SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

Hossein Borghaei, Mary W. Redman, Karen Kelly, Saima N. Waqar, Francisco Robert, Gauri J. Kiefer, Philip J. Stella, Katherine Minichiello, David R. Gandara, Roy S. Herbst, Vassiliki A. Papadimitrakopoulou

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science